Cardlytics (NASDAQ:CDLX) Shares Up 4.7%

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report)'s stock price rose 4.7% on Thursday . The company traded as high as $13.99 and last traded at $13.95. Approximately 315,639 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 1,618,547 shares. The stock had previously closed at $13.32.

Analyst Upgrades and Downgrades

CDLX has been the subject of a number of research analyst reports. Lake Street Capital upped their price target on shares of Cardlytics from $13.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, March 15th. Craig Hallum upgraded shares of Cardlytics from a "hold" rating to a "buy" rating and increased their price target for the stock from $10.00 to $18.00 in a research note on Friday, March 15th. Finally, Needham & Company LLC increased their price target on shares of Cardlytics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $13.60.

Cardlytics Stock Performance

The company has a debt-to-equity ratio of 1.91, a current ratio of 1.31 and a quick ratio of 1.31. The stock's 50 day simple moving average is $10.14 and its two-hundred day simple moving average is $9.79. The stock has a market cap of $634.29 million, a P/E ratio of -4.16 and a beta of 1.44.

Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $89.17 million during the quarter. Cardlytics had a negative net margin of 43.56% and a negative return on equity of 25.38%.

Insider Activity

In related news, major shareholder Clifford Sosin sold 17,155 shares of the company's stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $7.00, for a total transaction of $120,085.00. Following the completion of the sale, the insider now owns 5,361,961 shares of the company's stock, valued at $37,533,727. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Clifford Sosin sold 17,155 shares of the company's stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $7.00, for a total value of $120,085.00. Following the completion of the transaction, the insider now owns 5,361,961 shares of the company's stock, valued at $37,533,727. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total value of $170,577.40. Following the transaction, the insider now owns 71,355 shares in the company, valued at $976,849.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 102,427 shares of company stock valued at $736,095. 0.78% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cardlytics

Several large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in Cardlytics by 238.4% in the 2nd quarter. FMR LLC now owns 1,428 shares of the company's stock worth $32,000 after acquiring an additional 1,006 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Cardlytics by 220.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,405 shares of the company's stock worth $32,000 after purchasing an additional 2,343 shares during the period. Point72 Middle East FZE purchased a new position in Cardlytics in the 4th quarter worth approximately $35,000. Point72 Hong Kong Ltd purchased a new position in Cardlytics in the 2nd quarter worth approximately $38,000. Finally, Comerica Bank purchased a new position in shares of Cardlytics during the third quarter valued at approximately $40,000. 68.10% of the stock is currently owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.